Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Halozyme Therapeutic 11388 SORRENTO VALLEY ROAD SAN DIEGO CA 92121-1345 USA

P: 858-794-8889 F: 858-704-8311

Description:

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.

Key Statistics

Overview:

Market Capitalization, $K 5,871,319
Shares Outstanding, K 142,335
Annual Sales, $ 267,590 K
Annual Net Income, $ 129,090 K
Last Quarter Sales, $ 136,460 K
Last Quarter Net Income, $ 91,460 K
60-Month Beta 1.43
% of Insider Shareholders 2.60%
% of Institutional Shareholders 89.92%
Float, K 138,634
% Float 97.40%

Growth:

1-Year Return 50.39%
3-Year Return 139.87%
5-Year Return 247.81%
5-Year Revenue Growth 98.13%
5-Year Earnings Growth 464.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.66 on 08/09/21
Next Earnings Date 11/01/21
Earnings Per Share ttm 1.72
EPS Growth vs. Prev Qtr 85.29%
EPS Growth vs. Prev Year 231.58%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

HALO Ratios

Ratio
Price/Earnings ttm 24.07
Price/Earnings forward -23.38
Price/Earnings to Growth N/A
Return-on-Equity % 230.77%
Return-on-Assets % 32.60%
Profit Margin % 48.24
Net Margin % -95.02
Debt/Equity 11.61
Price/Sales 22.02
Price/Cash Flow 38.74
Price/Book 50.20
Book Value/Share 0.84
Interest Coverage 7.34
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar